title: Brittle asthma.
abstract: Brittle asthma is a rare form of severe asthma characterized by a wide variation of Peak Expiratory Flow (PEF), in spite of heavy doses of steroides. Brittle asthmatic patients had very serious and often, life threatening, attacks. Type 1 brittle asthma is characterized by a mantained PEF variability despite therapy, and it affected mostly female, aged between 15 and 55 years. Type 1 is associated to skin prick tests positivity and food intolerance. Several studies have referred a correlation with personality disorders. The patients affected with type 1 have high morbidity, and frequently they have hospital admission for assessment and stabilitation their asthmatic condition. Type 2 brittle asthma is characterized by acute attacks that are very severe and could led to death or mechanical ventilation for respiratory insufficiency. Brittle asthma is very difficult to recognize and to treat. In type 1 brittle asthma, the therapy is based on inhaled and/or oral steroids, and beta2-agonists, used with an inhaler or with subcutaneous infusion. The patients affected with type 1 had to be nearly monitered and treated. Patients affected with type 2 brittle asthma, are mostly free by simptoms, but they have severe attacks that led them to emergency treatment. Brittle asthma is a rare form of severe asthma, that the clinicians may recognize and treat very strictly, because of high morbidity and mortality.
authors.affiliation: University La Sapienza - Rome (Italy).
authors.forename: E
authors.initials: E
authors.lastname: Graziani
authors.forename: A
authors.initials: A
authors.lastname: Petroianni
authors.forename: C
authors.initials: C
authors.lastname: Terzano
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D001249:Asthma / Q000145:classification / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D000318:Adrenergic beta-Agonists; D020024:Leukotriene Antagonists